Form 4 for ELVN Enliven Therapeutics, Inc.
Accepted 2026-03-11 00:00:00 ET · period of report 2026-03-09 · accession 0001701247-26-000003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-03-11 | 2026-03-09+ | ELVN | Collins Helen Louise | Chief MEDICAL Off | S - Sale+OE | $30.06 | -40.0K | 25.0K | -62% | -$1.20M |
| DM | 2026-03-11 | 2026-03-09+ | ELVN | Collins Helen Louise | Chief MEDICAL Off | M - OptEx | $2.48 | +40.0K | 54.9K | +269% | +$99.2K |
| DM | 2026-03-11 | 2026-03-09+ | ELVN | Collins Helen Louise | Chief MEDICAL Off | M - OptEx | $0.00 | -40.0K | 191.4K | -17% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-10 | S | D | 10,129 | $30.19 | 25,000 | D | — | — | (F5) This transaction was executed in multiple trades at prices ranging from $30.00 to $30.56. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F4) These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. |
| 2 | Common | Common Stock | 2026-03-10 | M | A | 10,129 | $2.48 | 35,129 | D | — | — | (F2) Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. |
| 3 | Common | Common Stock | 2026-03-09 | S | D | 29,871 | $30.02 | 25,000 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $30.00 to $30.10. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F4) These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. |
| 4 | Common | Common Stock | 2026-03-09 | M | A | 29,871 | $2.48 | 54,871 | D | — | — | (F2) Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. |
| 5 | Derivative | Stock Option (right to buy) | 2026-03-10 | M | D | 10,129 | $0.00 | 181,268 | D | $2.48 · — to 2031-06-17 | 10,129 Common Stock | (F6) All of the shares subject to this option are fully vested and exercisable as of the date hereof. |
| 6 | Derivative | Stock Option (right to buy) | 2026-03-09 | M | D | 29,871 | $0.00 | 191,397 | D | $2.48 · — to 2031-06-17 | 29,871 Common Stock | (F6) All of the shares subject to this option are fully vested and exercisable as of the date hereof. |